Merck invests over €50 million in flagship pharmaceutical packaging building in Darmstadt
Focus on Merck’s brands Glucophage, Concor and Euthyrox to meet increasing patient needs in the areas of diabetes, cardiovascular diseases and thyroid disorders.
Merck is investing more than €50 million in a state-of-the-art packaging building at its pharmaceutical manufacturing site in Darmstadt, Germany.
“Sustained growth of healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders continues to meet increased patient demand,” said Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare. “We are committed to helping to ensure that our medicines are always available to patients who need them. Therefore, we are investing in our manufacturing and supply network across the world to continuously adapt our footprint and capacity while leveraging new technologies to always better serve patients.”
“Darmstadt is our largest site and centre of excellence for oral and solid dosage forms and this new packaging building will be the place to implement state-of-the-art smart packaging technology,” added Thierry Hulot, Head of Global Manufacturing & Supply at the biopharma business of Merck.
With its state-of-the art, flexible and modern technology, this new centre of excellence will enable the packaging of more than 400 million blisters or 150 million packs annually. It will use energy-saving technologies, and forms part of Merck’s strategy to sustain its leading position in healthcare manufacturing. It is aligned with other investments across Merck’s manufacturing network worldwide and aims to further strengthen the company’s manufacturing footprint and upgrade its services for patients. Construction of the 15,000 m2 packaging building is planned to be completed by the end of 2017 and expected to be operational as of mid-2018. The centre will be designed to comply with the highest international GMP quality standards.
In Darmstadt, Merck is committed to invest around €1 billion until 2020 and this investment is part of this initiative.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance